SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes
Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.
Posted inCardiology news Specialties
Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial
In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.
Posted inCardiology Specialties
Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors
This article explores the incidence of erythrocytosis and thromboembolic risk in heart failure patients treated with SGLT2 inhibitors, revealing a higher incidence of erythrocytosis but no associated increase in thromboembolic events over one year.
Posted inCardiology Clinical Updates news Specialties
Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction
The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.